Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

Fig. 6

In vitro synergism analysis of the three-drug combination (BKM120, MEK162 and irinotecan) in cells. (a) On the left, the blue matrices show the observed values of cytotoxicity (SRB assay) for BKM120 and MEK162 without (top) or with 4 nM SN38 (bottom). Middle panels, synergy matrices show the percentage of cytotoxicity due to drug synergism. Right panel, the matrix shows the percentage of cytotoxicity due to irinotecan addition. (b) Western blot analysis showing the inhibition of ERK and AKT phosphorylation in HCT116 cells incubated with BKM120, MEK162 and SN38 (alone or in combination as indicated)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us